Cargando…
Targeted therapy for HER2 positive breast cancer
INTRODUCTION: Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703272/ https://www.ncbi.nlm.nih.gov/pubmed/23731980 http://dx.doi.org/10.1186/1756-8722-6-38 |
_version_ | 1782275879983906816 |
---|---|
author | Incorvati, Jason A Shah, Shilpan Mu, Ying Lu, Janice |
author_facet | Incorvati, Jason A Shah, Shilpan Mu, Ying Lu, Janice |
author_sort | Incorvati, Jason A |
collection | PubMed |
description | INTRODUCTION: Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two hallmark time frames. The first occurred during the mid to late 1980’s when hormonal therapy was introduced as a treatment for ER/PR positive breast cancer. The second occurred in the late 1990’s when trastuzumab was introduced in treating HER2 positive breast cancer. These remarkable accomplishments in developing novel targeted therapies for breast cancer, along with a better understanding of the disease biology have improved disease outcome over the past 20 years. This article reviews the data presented at 2012 American Society of Clinical Oncology and 2012 San Antonio Breast Cancer Symposium regarding progress made in the field of HER2 positive breast cancer and examines the future of HER2 targeted therapy. |
format | Online Article Text |
id | pubmed-3703272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37032722013-07-07 Targeted therapy for HER2 positive breast cancer Incorvati, Jason A Shah, Shilpan Mu, Ying Lu, Janice J Hematol Oncol Review INTRODUCTION: Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two hallmark time frames. The first occurred during the mid to late 1980’s when hormonal therapy was introduced as a treatment for ER/PR positive breast cancer. The second occurred in the late 1990’s when trastuzumab was introduced in treating HER2 positive breast cancer. These remarkable accomplishments in developing novel targeted therapies for breast cancer, along with a better understanding of the disease biology have improved disease outcome over the past 20 years. This article reviews the data presented at 2012 American Society of Clinical Oncology and 2012 San Antonio Breast Cancer Symposium regarding progress made in the field of HER2 positive breast cancer and examines the future of HER2 targeted therapy. BioMed Central 2013-06-03 /pmc/articles/PMC3703272/ /pubmed/23731980 http://dx.doi.org/10.1186/1756-8722-6-38 Text en Copyright © 2013 Incorvati et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Incorvati, Jason A Shah, Shilpan Mu, Ying Lu, Janice Targeted therapy for HER2 positive breast cancer |
title | Targeted therapy for HER2 positive breast cancer |
title_full | Targeted therapy for HER2 positive breast cancer |
title_fullStr | Targeted therapy for HER2 positive breast cancer |
title_full_unstemmed | Targeted therapy for HER2 positive breast cancer |
title_short | Targeted therapy for HER2 positive breast cancer |
title_sort | targeted therapy for her2 positive breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703272/ https://www.ncbi.nlm.nih.gov/pubmed/23731980 http://dx.doi.org/10.1186/1756-8722-6-38 |
work_keys_str_mv | AT incorvatijasona targetedtherapyforher2positivebreastcancer AT shahshilpan targetedtherapyforher2positivebreastcancer AT muying targetedtherapyforher2positivebreastcancer AT lujanice targetedtherapyforher2positivebreastcancer |